Stephen B. Hanauer | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Stephen B. Hanauer is active.

Explore More

Publication

Featured researches published by Stephen B. Hanauer.

Archive | 2007

Uses and compositions for treatment of crohn's disease

Paul F. Pollack; Rebecca S. Hoffman; Cheryl Renz; Susan K. Paulson; Zhuoying Peng; William J. Sandborn; Stephen B. Hanauer; Paul Rutgeerts

Gastroenterology | 2012

943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial

B. Feagan; P. Rutgeerts; Bruce E. Sands; J.-F. Colombel; W. Sandborn; Stephen B. Hanauer; G. Van Assche; Jeffrey L. Axler; Hyo-Jong Kim; S. Danese; I. Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh

Archive | 2011

Effi cacy of Biological Therapies in Infl ammatory Bowel Disease: Systematic Review and Meta-Analysis

Alexander C. Ford; W. Sandborn; Khurram J. Khan; Stephen B. Hanauer; Nicholas J. Talley; Paul Moayyedi

The American Journal of Gastroenterology | 2001

Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn’s disease

Paul Rutgeerts; Lloyd Mayer; Stephan Schreiber; Warren Bao; Mohan Bala; Greg Keenan; Allan Olson; Stephen B. Hanauer

The American Journal of Gastroenterology Supplements | 2016

Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy

David T. Rubin; Stephen B. Hanauer; Gary R. Lichtenstein; Dermot McGovern; Miguel D. Regueiro; Scott B. Snapper; Stephan R. Targan

The American Journal of Gastroenterology Supplements | 2016

Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools

Miguel Regueiro; Julia B. Greer; Stephen B. Hanauer

Archive | 2015

PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease

Guillaume Bouguen; Barrett G. Levesque; B. Feagan; Arthur Kavanaugh; Stephen B. Hanauer; W. Sandborn

Archive | 2009

CLINICAL—ALIMENTARY TRACT Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis

W. Sandborn; Jaroslaw Regula; B. Feagan; Elena Belousova; Njegica Jojic; Milan Lukas; Bruce Yacyshyn; Piotr Krzeski; Christi A. Messer; Stephen B. Hanauer; Russian Federation; Gamble Pharmaceuticals

Archive | 2009

CLINICAL—ALIMENTARY TRACT Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

W. Sandborn; Paul Rutgeerts; B. Feagan; W. Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin J. Horgan; Daniel Rachmilewitz; Stephen B. Hanauer; Gary R. Lichtenstein; Willem J. de Villiers; Bruce E. Sands; Jean-Frédéric Colombel

Archive | 2007

CLINICAL-ALIMENTARY TRACT A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis

Scott E. Plevy; Bruce Salzberg; Gert Van Assche; Miguel Regueiro; Daniel W. Hommes; William J. Sandborn; Stephen B. Hanauer; Stephan R. Targan; Lloyd Mayer; Uma Mahadevan; Matthew Frankel; James Lowder

Explore More